{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:23:02Z","timestamp":1793834582716,"version":"4.6.1"},"reference-count":214,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Atherosclerosis is a chronic inflammatory disease characterized by the accumulation of lipids, fibrous elements, and cellular debris in the blood vessels. The response-to-retention hypothesis, the leading theory on the pathogenesis of this cardiovascular disease, describes the initial event in atherosclerosis as when Apolipoprotein B-containing lipoproteins, including endogenous and dietary-derived lipoproteins, bind to the inner arterial wall, the tunica intima. The subsequent lipoprotein modifications trigger an immune response that promotes atherosclerotic plaque formation. Despite the prevalence of atherosclerosis globally, and its vascular nature, therapies directed to the artery wall are limited. Immunotherapies, most notably monoclonal antibodies (mAbs), are of special interest due to their high specificity, reliability and proven success in a variety of diseases. However, current mAbs for atherosclerosis tend to target disease risk factors, notably inflammation and circulating lipoprotein levels, rather than address the root cause of atherosclerosis. These treatments result in a phenomenon known as residual risk, defined by the occurrence of severe cardiovascular events, including myocardial infarction, during treatment. Per the \u201cresponse to retention\u201d hypothesis, a plausible strategy for atherosclerosis would be blocking cholesterol retention <jats:italic>per se<\/jats:italic> at the arterial extracellular matrix level to complement lipid-lowering therapies. One such immunotherapy is the chP3R99 mAb, which can bind to pro-atherogenic proteoglycan sugar branches, thus competitively inhibiting lipid retention at these sites. The aim of this review is twofold: 1) To provide a summary of mAbs and other therapies used for atherosclerosis treatment, focusing on anti-inflammatory and lipid-lowering therapies, and 2) To review data on the structural characteristics, theory, and therapeutic effect of the chP3R99 mAb.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1485801","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T05:23:58Z","timestamp":1749446638000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Atherosclerosis: from lipid-lowering and anti-inflammatory therapies to targeting arterial retention of ApoB-containing lipoproteins"],"prefix":"10.3389","volume":"16","author":[{"given":"Gala","family":"Araujo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leidy Marian","family":"Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Martin-Ozimek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosdel","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer D.","family":"Proctor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.15.5.551","article-title":"The response-to-retention hypothesis of early atherogenesis","volume":"15","author":"Williams","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41569-019-0169-2","article-title":"Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities","volume":"16","author":"B\u00e4ck","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20150844","article-title":"The arterial microenvironment: the where and why of atherosclerosis","volume":"473","author":"Yurdagul","year":"2016","journal-title":"Biochem J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.numecd.2011.09.007","article-title":"Retention of atherogenic lipoproteins in the artery wall and its role in atherogenesis","volume":"22","author":"Fogelstrand","year":"2012","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11154-008-9078-0","article-title":"Proteoglycan mediated lipoprotein retention: a mechanism of diabetic atherosclerosis","volume":"9","author":"Tannock","year":"2008","journal-title":"Rev Endocr Metab Disord"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.clim.2009.07.016","article-title":"Innate immune signals in atherosclerosis","volume":"134","author":"Lundberg","year":"2010","journal-title":"Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J BioMed Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"100371","DOI":"10.1016\/j.ajpc.2022.100371","article-title":"There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness","volume":"12","author":"Makover","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11154611","article-title":"Newer and emerging LDL-C lowering agents and implications for ASCVD residual risk","volume":"11","author":"Rikhi","year":"2022","journal-title":"J Clin Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.306471","article-title":"From lipids to inflammation: new approaches to reducing atherosclerotic risk","volume":"118","author":"Shapiro","year":"2016","journal-title":"Circ Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.12.47","article-title":"The quest for immunotherapy in atherosclerosis: CANTOS study, interleukin-1beta and vascular inflammation","volume":"10","author":"Bermudez","year":"2018","journal-title":"J Thorac Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2022.0198","article-title":"New, novel lipid-lowering agents for reducing cardiovascular risk: beyond statins","volume":"46","author":"Kim","year":"2022","journal-title":"Diabetes Metab J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.acvd.2019.11.001","article-title":"Antibody-based immunotherapy targeting cytokines and atherothrombotic cardiovascular diseases","volume":"113","author":"Ait-Oufella","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1161\/ATVBAHA.111.238659","article-title":"Antiatherosclerotic effect of an antibody that binds to extracellular matrix glycosaminoglycans","volume":"32","author":"Soto","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.307611","article-title":"Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease","volume":"118","author":"Herrington","year":"2016","journal-title":"Circ Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2016.185","article-title":"Inflammatory processes in cardiovascular disease: a route to targeted therapies","volume":"14","author":"Ruparelia","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.05.011","article-title":"Progression of early subclinical atherosclerosis (PESA) study: JACC focus seminar 7\/8","volume":"78","author":"Ibanez","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R800099-JLR200","article-title":"Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis","author":"Libby","year":"2009","journal-title":"J Lipid Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30117-0","article-title":"Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study","volume":"8","author":"Song","year":"2020","journal-title":"Lancet Glob Health"},{"key":"B21","doi-asserted-by":"publisher","first-page":"634983","DOI":"10.1155\/2015\/634983","article-title":"Rapid progression of coronary atherosclerosis: A review","volume":"2015","author":"Shah","year":"2015","journal-title":"Thrombosis."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.525675","article-title":"Cardiovascular risk factors and atherosclerosis in young women: atherosclerosis risk factors in female youngsters (ARFY study)","volume":"40","author":"Knoflach","year":"2009","journal-title":"Stroke."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.959285","article-title":"Hypertension as a risk factor for atherosclerosis: Cardiovascular risk assessment","volume":"9","author":"Poznyak","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2016.11.009","article-title":"Hypercholesterolemia as a risk factor for cardiovascular disease: current controversial therapeutic management","volume":"47","author":"Zarate","year":"2016","journal-title":"Arch Med Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2013an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"B26","article-title":"Response to injury and atherogenesis","volume":"86","author":"Ross","year":"1977","journal-title":"Am J Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000330","article-title":"The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity","volume":"27","author":"Boren","year":"2016","journal-title":"Curr Opin Lipidol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.307609","article-title":"How an artery heals","volume":"117","author":"Williams","year":"2015","journal-title":"Circ Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1201\/9780203748831-3","article-title":"Cellular interactions of lipoproteins with the vascular endothelium: endocytosis and transcytosis","volume":"5","author":"Simionescu","year":"1991","journal-title":"Targeted Diagn Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.96.6.1677","article-title":"Visualization of the binding, endocytosis, and transcytosis of low-density lipoprotein in the arterial endothelium in situ","volume":"96","author":"Vasile","year":"1983","journal-title":"J Cell Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvv218","article-title":"A novel assay uncovers an unexpected role for SR-BI in LDL transcytosis","volume":"108","author":"Armstrong","year":"2015","journal-title":"Cardiovasc Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"13516","DOI":"10.1038\/ncomms13516","article-title":"Genome-wide RNAi screen reveals ALK1 mediates LDL uptake and transcytosis in endothelial cells","volume":"7","author":"Kraehling","year":"2016","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1140-4","article-title":"SR-B1 drives endothelial cell LDL transcytosis via DOCK4 to promote atherosclerosis","volume":"569","author":"Huang","year":"2019","journal-title":"Nature."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s44161-023-00266-2","article-title":"Genetic or therapeutic neutralization of ALK1 reduces LDL transcytosis and atherosclerosis in mice","volume":"2","author":"Lee","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI145800","article-title":"Eruptive xanthoma model reveals endothelial cells internalize and metabolize chylomicrons, leading to extravascular triglyceride accumulation","volume":"131","author":"Cabodevilla","year":"2021","journal-title":"J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000143859.75035.5a","article-title":"Arterial permeability and efflux of apolipoprotein B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confocal microscopy","volume":"24","author":"Proctor","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1046\/j.1365-2362.1998.00317.x","article-title":"Retention of fluorescent-labelled chylomicron remnants within the intima of the arterial wall\u2013evidence that plaque cholesterol may be derived from post-prandial lipoproteins","volume":"28","author":"Proctor","year":"1998","journal-title":"Eur J Clin Invest."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-024-01111-0","article-title":"Apolipoprotein B-containing lipoproteins in atherogenesis","volume":"2025","author":"Boren","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170453","article-title":"Dynamic metabolism of endothelial triglycerides protects against atherosclerosis in mice","volume":"134","author":"Boutagy","year":"2024","journal-title":"J Clin Invest."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176347","article-title":"Lipid droplets in the endothelium: The missing link between metabolic syndrome and cardiovascular disease","volume":"134","author":"Jaffe","year":"2024","journal-title":"J Clin Invest."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1172\/JCI173160","article-title":"Endothelial lipid droplets suppress eNOS to link high fat consumption to blood pressure elevation","volume":"133","author":"Kim","year":"2023","journal-title":"J Clin Invest"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/00041433-200210000-00001","article-title":"Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis","volume":"13","author":"Proctor","year":"2002","journal-title":"Curr Opin Lipidol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e003434","DOI":"10.1161\/JAHA.112.003434","article-title":"Arterial retention of remnant lipoproteins ex vivo is increased in insulin resistance because of increased arterial biglycan and production of cholesterol-rich atherogenic particles that can be improved by ezetimibe in the JCR: LA-cp rat","volume":"1","author":"Mangat","year":"2012","journal-title":"J Am Heart Assoc."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000084638.14534.0A","article-title":"Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritab le hyperlipidemic rabbits","volume":"23","author":"Proctor","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1083\/jcb.201412052","article-title":"Recent insights into the cellular biology of atherosclerosis","volume":"209","author":"Tabas","year":"2015","journal-title":"J Cell Biol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1464-5491.2010.03138.x","article-title":"Increased risk of cardiovascular disease in Type 1 diabetes: arterial exposure to remnant lipoproteins leads to enhanced deposition of cholesterol and binding to glycated extracellular matrix proteoglycans","volume":"28","author":"Mangat","year":"2011","journal-title":"Diabetes Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(98)00107-5","article-title":"Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis","volume":"139","author":"Camejo","year":"1998","journal-title":"Atherosclerosis."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nature00804","article-title":"Subendothelial retention of atherogenic lipoproteins in early atherosclerosis","volume":"417","author":"Skalen","year":"2002","journal-title":"Nature."},{"key":"B51","doi-asserted-by":"publisher","first-page":"36","DOI":"10.20944\/preprints201806.0239.v1","article-title":"ApoB-100 lipoprotein complex formation with intima proteoglycans as a cause of atherosclerosis and its possible ex vivo evaluation as a disease biomarker","volume":"5","author":"Hurt-Camejo","year":"2018","journal-title":"J Cardiovasc Dev Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/(SICI)1096-8628(19980226)76:1<79::AID-AJMG15>3.0.CO;2-M","article-title":"Genetic heterogeneity in familial hypobetalipoproteinemia: linkage and non-linkage to the apoB gene in Caucasian families","volume":"76","author":"Pulai","year":"1998","journal-title":"Am J Med Genet"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.82.24.8340","article-title":"Human apolipoprotein B-100: cloning, analysis of liver mRNA, and assignment of the gene to chromosome 2","volume":"82","author":"Law","year":"1985","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R100068200","article-title":"Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins","volume":"277","author":"Fisher","year":"2002","journal-title":"J Biol Chem"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)35646-1","article-title":"the major protein component of triglyceride-rich and low density lipoproteins","volume":"267","author":"Chan","year":"1992","journal-title":"J Biol Chem"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1847","article-title":"Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100","volume":"101","author":"Boren","year":"1998","journal-title":"J Clin Invest."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M204053200","article-title":"Identification of the proteoglycan binding site in apolipoprotein B48","volume":"277","author":"Flood","year":"2002","journal-title":"J Biol Chem"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000001140","article-title":"Predictive utility of remnant cholesterol in atherosclerotic cardiovascular disease","volume":"39","author":"Proctor","year":"2024","journal-title":"Curr Opin Cardiol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/joim.2015.278.issue-5","article-title":"Regulation of atherosclerotic plaque inflammation","volume":"278","author":"Back","year":"2015","journal-title":"J Intern Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3343","article-title":"Self-renewing resident arterial macrophages arise from embryonic CX3CR1(+) precursors and circulating monocytes immediately after birth","volume":"17","author":"Ensan","year":"2016","journal-title":"Nat Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9091221","article-title":"Macrophages and foam cells: brief overview of their role, linkage, and targeting potential in atherosclerosis","volume":"9","author":"Poznyak","year":"2021","journal-title":"Biomedicines."},{"key":"B62","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3390\/cells9030584","article-title":"Signaling Pathways Key Genes Involved Regul foam Cell Formation Atherosclerosis","volume":"9","author":"Poznyak","year":"2020","journal-title":"Cells"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119568","article-title":"The role of macrophages in atherosclerosis: pathophysiologic mechanisms and treatment considerations","volume":"24","author":"Theofilis","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0768-4","article-title":"Limited proliferation capacity of aortic intima resident macrophages requires monocyte recruitment for atherosclerotic plaque progression","volume":"21","author":"Williams","year":"2020","journal-title":"Nat Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1196033","article-title":"Monocyte-endothelial cell interactions in vascular and tissue remodeling","volume":"14","author":"Medrano-Bosch","year":"2023","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.06.009","article-title":"Immune effector mechanisms implicated in atherosclerosis: from mice to humans","volume":"38","author":"Libby","year":"2013","journal-title":"Immunity."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1172\/JCI157011","article-title":"Through the layers: how macrophages drive atherosclerosis across the vessel wall","volume":"132","author":"Susser","year":"2022","journal-title":"J Clin Invest."},{"key":"B68","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/CIRCRESAHA.115.306361","article-title":"Vascular smooth muscle cells in atherosclerosis","volume":"118","author":"Bennett","year":"2016","journal-title":"Circ Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063346","article-title":"Pathophysiology of Atherosclerosis","volume":"23","author":"Jebari-Benslaiman","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2174\/1874091X00802010135","article-title":"Biosynthesis of natural and hyperelongated chondroitin sulfate glycosaminoglycans: new insights into an elusive process","volume":"2","author":"Little","year":"2008","journal-title":"Open Biochem J"},{"key":"B71","doi-asserted-by":"publisher","first-page":"118552","DOI":"10.1016\/j.atherosclerosis.2024.118552","article-title":"Response to retention hypothesis as a source of targets for arterial wall-directed therapies to prevent atherosclerosis: A critical review","volume":"397","author":"Kumarapperuma","year":"2024","journal-title":"Atherosclerosis."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.119.312434","article-title":"Smooth muscle cells contribute the majority of foam cells in apoE (Apolipoprotein E)-deficient mouse atherosclerosis","volume":"39","author":"Wang","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.048378","article-title":"Single-cell genomics reveals a novel cell state during smooth muscle cell phenotypic switching and potential therapeutic targets for atherosclerosis in mouse and human","volume":"142","author":"Pan","year":"2020","journal-title":"Circulation."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.301312","article-title":"Inflammatory and immune responses in the arterial media","volume":"116","author":"Tellides","year":"2015","journal-title":"Circ Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.3390\/ijms21113946","article-title":"Matrix metalloproteinases as biomarkers of atherosclerotic plaque instability","volume":"21","author":"Olejarz","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.613780","article-title":"Overview of oxLDL and its impact on cardiovascular health: focus on atherosclerosis","volume":"11","author":"Poznyak","year":"2020","journal-title":"Front Pharmacol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"5293","DOI":"10.3390\/ijms20215293","article-title":"Immunobiology of atherosclerosis: a complex net of interactions","volume":"20","author":"Herrero-Fernandez","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020452","article-title":"Functional phenotypes of intraplaque macrophages and their distinct roles in atherosclerosis development and atheroinflammation","volume":"10","author":"Mushenkova","year":"2022","journal-title":"Biomedicines"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-018-0812-9","article-title":"Andrographolide ameliorates atherosclerosis by suppressing pro-inflammation and ROS generation-mediated foam cell formation","volume":"41","author":"Wu","year":"2018","journal-title":"Inflammation."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.2A1017-407RR","article-title":"Oxidized LDL phagocytosis during foam cell formation in atherosclerotic plaques relies on a PLD2-CD36 functional interdependence","volume":"103","author":"Ganesan","year":"2018","journal-title":"J Leukoc Biol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.00590","article-title":"Dan-Lou Prescription Inhibits Foam Cell Formation Induced by ox-LDL via the TLR4\/NF-kappaB and PPARgamma Signaling Pathways","volume":"9","author":"Gao","year":"2018","journal-title":"Front Physiol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ai.2016.02.001","article-title":"Malondialdehyde epitopes as targets of immunity and the implications for atherosclerosis","volume":"131","author":"Papac-Milicevic","year":"2016","journal-title":"Adv Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R800066-JLR200","article-title":"The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges","author":"Greaves","year":"2009","journal-title":"J Lipid Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2016.09.002","article-title":"Mechanism and regulation of NLRP3 inflammasome activation","volume":"41","author":"He","year":"2016","journal-title":"Trends Biochem Sci"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.910687","article-title":"Targeted deletions of cyclooxygenase-2 and atherogenesis in mice","volume":"121","author":"Hui","year":"2010","journal-title":"Circulation."},{"key":"B86","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s40828-022-00163-4","article-title":"Macrophages: shapes and functions","volume":"8","author":"Lendeckel","year":"2022","journal-title":"ChemTexts."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.2174\/1570161052773861","article-title":"Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture","volume":"3","author":"Boyle","year":"2005","journal-title":"Curr Vasc Pharmacol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.108.179697","article-title":"Oxidized low-density lipoprotein and atherosclerosis","volume":"30","author":"Steinberg","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00584-1","article-title":"How the immune system shapes atherosclerosis: roles of innate and adaptive immunity","volume":"22","author":"Roy","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B90","doi-asserted-by":"crossref","DOI":"10.1016\/S0092-8674(01)00238-0","article-title":"Atherosclerosis. the road ahead","volume":"104","author":"Glass","year":"2001","journal-title":"Cell."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.21.1.108","article-title":"LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis","volume":"21","author":"Zhou","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/nm1601","article-title":"Mast cells promote atherosclerosis by releasing proinflammatory cytokines","volume":"13","author":"Sun","year":"2007","journal-title":"Nat Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00281-013-0400-x","article-title":"Dendritic cells in atherosclerosis","volume":"36","author":"Subramanian","year":"2014","journal-title":"Semin Immunopathol."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-4141(199905)29:05<1543::AID-IMMU1543>3.0.CO;2-R","article-title":"Antigen presentation by T cells versus professional antigen-presenting cells (APC): differential consequences for T cell activation and subsequent T cell-APC interactions","volume":"29","author":"Taams","year":"1999","journal-title":"Eur J Immunol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1146\/annurev.immunol.18.1.767","article-title":"Immunobiology of dendritic cells","volume":"18","author":"Banchereau","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.303566","article-title":"Dendritic cells in atherosclerosis: evidence in mice and humans","volume":"35","author":"Zernecke","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/nri2379","article-title":"T-cell activation by dendritic cells in the lymph node: lessons from the movies","volume":"8","author":"Bousso","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"9582430","DOI":"10.1155\/2016\/9582430","article-title":"Macrophages and their role in atherosclerosis: pathophysiology and transcriptome analysis","volume":"2016","author":"Bobryshev","year":"2016","journal-title":"BioMed Res Int"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00095","article-title":"T-cells specific for a self-peptide of apoB-100 exacerbate aortic atheroma in murine atherosclerosis","volume":"8","author":"Shaw","year":"2017","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.124.319845","article-title":"T-cell\/B-cell interactions in atherosclerosis","volume":"44","author":"Jones","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000245830.29764.84","article-title":"cells in atherogenesis: for better or for worse","volume":"26","author":"Robertson","year":"2006","journal-title":"T Arterioscler Thromb Vasc Biol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.9.3893","article-title":"T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein","volume":"92","author":"Stemme","year":"1995","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.3.821","article-title":"Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis","volume":"92","author":"Palinski","year":"1995","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.16.8.1074","article-title":"Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits","volume":"16","author":"Ameli","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s44161-022-00063-3","article-title":"Single cell transcriptomics and TCR reconstruction reveal CD4 T cell response to MHC-II-restricted APOB epitope in human cardiovascular disease","volume":"1","author":"Saigusa","year":"2022","journal-title":"Nat Cardiovasc Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.031420","article-title":"Regulatory CD4(+) T cells recognize major histocompatibility complex class II molecule-restricted peptide epitopes of apolipoprotein B","volume":"138","author":"Kimura","year":"2018","journal-title":"Circulation."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00798.2016","article-title":"Atheroprotective vaccination with MHC-II-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells","volume":"312","author":"Kimura","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00493","article-title":"Atheroprotective vaccination with MHC-II restricted peptides from apoB-100","volume":"4","author":"Tse","year":"2013","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020446","article-title":"ApoB-specific CD4(+) T cells in mouse and human atherosclerosis","volume":"10","author":"Marchini","year":"2021","journal-title":"Cells."},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/nri1882","article-title":"The immune response in atherosclerosis: a double-edged sword","volume":"6","author":"Hansson","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature."},{"key":"B112","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41569-020-0352-5","article-title":"T cell subsets and functions in atherosclerosis","volume":"17","author":"Saigusa","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0021-9150(99)00011-8","article-title":"Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines","volume":"145","author":"Frostegard","year":"1999","journal-title":"Atherosclerosis."},{"key":"B114","doi-asserted-by":"publisher","first-page":"157534","DOI":"10.1100\/2012\/157534","article-title":"T lymphocyte autoreactivity in inflammatory mechanisms regulating atherosclerosis","volume":"2012","author":"Profumo","year":"2012","journal-title":"ScientificWorldJournal."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2004.tb00241.x","article-title":"Atherosclerosis and the immune system","volume":"93","author":"Hansson","year":"2004","journal-title":"Acta Paediatr Suppl"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409015102","article-title":"-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses","volume":"102","author":"116. Buono","year":"2005","journal-title":"T Proc Natl Acad Sci U S A."},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/nm1343","article-title":"Natural regulatory T cells control the development of atherosclerosis in mice","volume":"12","author":"Ait-Oufella","year":"2006","journal-title":"Nat Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1172\/JCI63891","article-title":"Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis","volume":"123","author":"Klingenberg","year":"2013","journal-title":"J Clin Invest."},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030997","article-title":"CD1d-dependent activation of NKT cells aggravates atherosclerosis","volume":"199","author":"Tupin","year":"2004","journal-title":"J Exp Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090545","article-title":"Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis","volume":"206","author":"Taleb","year":"2009","journal-title":"J Exp Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/ni710","article-title":"NKT cells derive from double-positive thymocytes that are positively selected by CD1d","volume":"2","author":"Gapin","year":"2001","journal-title":"Nat Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.001347","article-title":"Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-deficient mice","volume":"127","author":"Kyaw","year":"2013","journal-title":"Circulation."},{"key":"B123","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/cells10010037","article-title":"CD8(+) T cells in atherosclerosis","volume":"10","author":"Schafer","year":"2020","journal-title":"Cells."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.94570","article-title":"The role of immune cells in different stages of atherosclerosis","volume":"21","author":"He","year":"2024","journal-title":"Int J Med Sci"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.304611","article-title":"CD8+ T cells regulate monopoiesis and circulating ly6C-high monocyte levels in atherosclerosis in mice","volume":"117","author":"Cochain","year":"2015","journal-title":"Circ Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005318","article-title":"Identification of apoB-100 peptide-specific CD8+ T cells in atherosclerosis","volume":"6","author":"Dimayuga","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1990.tb00794.x","article-title":"Immunohistochemical characterization of inflammatory cells associated with advanced atherosclerosis","volume":"17","author":"Ramshaw","year":"1990","journal-title":"Histopathology."},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00387","article-title":"Artery tertiary lymphoid organs: powerhouses of atherosclerosis immunity","volume":"7","author":"Yin","year":"2016","journal-title":"Front Immunol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00281-004-0185-z","article-title":"Natural antibodies and the autoimmunity of atherosclerosis","volume":"26","author":"Binder","year":"2005","journal-title":"Springer Semin Immunopathol."},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2001","article-title":"The immune system in atherosclerosis","volume":"12","author":"Hansson","year":"2011","journal-title":"Nat Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-018-0106-9","article-title":"The role of B cells in atherosclerosis","volume":"16","author":"Sage","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000033","article-title":"Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis","volume":"185","author":"Kyaw","year":"2010","journal-title":"J Immunol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3109\/07853890.2014.900272","article-title":"Multiple potential roles for B cells in atherosclerosis","volume":"46","author":"Sage","year":"2014","journal-title":"Ann Med"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.111.248542","article-title":"B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions","volume":"109","author":"Kyaw","year":"2011","journal-title":"Circ Res"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100155","article-title":"B cell depletion reduces the development of atherosclerosis in mice","volume":"207","author":"Ait-Oufella","year":"2010","journal-title":"J Exp Med"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M600361-JLR200","article-title":"Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events","volume":"48","author":"Tsimikas","year":"2007","journal-title":"J Lipid Res"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3233\/HAB-2009-0202","article-title":"Autoantibodies to oxidized low density lipoprotein in relation with coronary artery disease","volume":"18","author":"Soto","year":"2009","journal-title":"Hum Antibodies."},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.303227","article-title":"Lymphocyte migration into atherosclerotic plaque","volume":"35","author":"Li","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61758","article-title":"Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis","volume":"122","author":"Koltsova","year":"2012","journal-title":"J Clin Invest."},{"key":"B140","doi-asserted-by":"publisher","first-page":"e032419","DOI":"10.1161\/JAHA.123.032419","article-title":"Monoclonal antibody chP3R99 reduces subendothelial retention of atherogenic lipoproteins in insulin-resistant rats: acute treatment versus long-term protection as an idiotypic vaccine for atherosclerosis","volume":"13","author":"Soto","year":"2024","journal-title":"J Am Heart Assoc."},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.29970","article-title":"Targeting arterial wall sulfated glycosaminoglycans in rabbit atherosclerosis with a mouse\/human chimeric antibody","volume":"6","author":"Soto","year":"2014","journal-title":"MAbs."},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.112.300444","article-title":"Induction of anti-anti-idiotype antibodies against sulfated glycosaminoglycans reduces atherosclerosis in apolipoprotein E-deficient mice","volume":"32","author":"Brito","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1264889","article-title":"Shedding light on the molecular and regulatory mechanisms of TLR4 signaling in endothelial cells under physiological and inflamed conditions","volume":"14","author":"Stierschneider","year":"2023","journal-title":"Front Immunol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3390\/cells11121935","article-title":"Regulation and dysregulation of endothelial permeability during systemic inflammation","volume":"11","author":"Hellenthal","year":"2022","journal-title":"Cells."},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2020.11.006","article-title":"Permeability of the endothelial barrier: identifying and reconciling controversies","volume":"27","author":"Claesson-Welsh","year":"2021","journal-title":"Trends Mol Med"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2024.1432719","article-title":"Low or oscillatory shear stress and endothelial permeability in atherosclerosis","volume":"15","author":"Chen","year":"2024","journal-title":"Front Physiol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/XCE.0000000000000172","article-title":"Atherosclerosis: integration of its pathogenesis as a self-perpetuating propagating inflammation: a review","volume":"8","author":"Poston","year":"2019","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.117.308611","article-title":"ATVB distinguished scientist award: how costimulatory and coinhibitory pathways shape atherosclerosis","volume":"37","author":"Ley","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.989431","article-title":"The role of immune checkpoints in cardiovascular disease","volume":"13","author":"Yousif","year":"2022","journal-title":"Front Pharmacol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2020.04.024","article-title":"Atherosclerosis and inflammation","volume":"155","author":"Pedro-Botet","year":"2020","journal-title":"New Ther approaches. Med Clin (Barc)."},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv759","article-title":"Inflammatory cytokines in atherosclerosis: current therapeutic approaches","volume":"37","author":"Tousoulis","year":"2016","journal-title":"Eur Heart J"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat Med"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2015.03.012","article-title":"Inflammasome inhibition: putting out the fire","volume":"21","author":"Netea","year":"2015","journal-title":"Cell Metab"},{"key":"B156","doi-asserted-by":"publisher","first-page":"19305","DOI":"10.1038\/s41598-021-98437-3","article-title":"The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages","volume":"11","author":"Zeng","year":"2021","journal-title":"Sci Rep"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat Med"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"B160","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jaccao.2022.11.011","article-title":"Atherosclerosis with immune checkpoint inhibitor therapy: evidence, diagnosis, and management: JACC: cardioOncology state-of-the-art review","volume":"4","author":"Suero-Abreu","year":"2022","journal-title":"JACC CardioOncol."},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.12.085","article-title":"T-cell co-stimulation by CD28-CD80\/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development","volume":"168","author":"Ewing","year":"2013","journal-title":"Int J Cardiol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3390\/ijms151120607","article-title":"Molecular mechanisms underlying the effects of statins in the central nervous system","volume":"15","author":"McFarland","year":"2014","journal-title":"Int J Mol Sci"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.07.006","article-title":"The forgotten majority: unfinished business in cardiovascular risk reduction","volume":"46","author":"Libby","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"B165","article-title":"The role of lipids and lipoproteins in atherosclerosis","volume-title":"Endotext. South dartmouth (MA)","author":"Linton","year":"2019"},{"key":"B166","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2710.2011.01244.x","article-title":"Optimal therapy for reduction of lipoprotein(a)","volume":"37","author":"Lippi","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"B168","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.acvd.2013.10.007","article-title":"PCSK9: From discovery to therapeutic applications","volume":"107","author":"Farnier","year":"2014","journal-title":"Arch Cardiovasc Dis"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.054","article-title":"The evolving future of PCSK9 inhibitors","volume":"72","author":"Rosenson","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034645","article-title":"Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy","volume":"138","author":"Pradhan","year":"2018","journal-title":"Circulation."},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Gaudet","year":"2014","journal-title":"Am J Cardiol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy122","article-title":"Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics","volume":"39","author":"Watts","year":"2018","journal-title":"Eur Heart J"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation."},{"key":"B174","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41574-018-0110-5","article-title":"Inhibiting PCSK9 - biology beyond LDL control","volume":"15","author":"Stoekenbroek","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1007\/s12471-017-0959-2","article-title":"Pathophysiology and treatment of atherosclerosis: Current view and future perspective on lipoprotein modification treatment","volume":"25","author":"Bergheanu","year":"2017","journal-title":"Neth Heart J"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20210318","article-title":"Nonfasting remnant cholesterol and cardiovascular disease risk prediction in Albertans: a prospective cohort study","volume":"11","author":"Weaver","year":"2023","journal-title":"CMAJ Open"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation."},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw152","article-title":"Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine","volume":"37","author":"Nordestgaard","year":"2016","journal-title":"Eur Heart J"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.60.3.473","article-title":"Atherogenesis: a postprandial phenomenon","volume":"60","author":"Zilversmit","year":"1979","journal-title":"Circulation."},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2018.09.062","article-title":"Nonfasting versus fasting lipid profile for cardiovascular risk prediction","volume":"51","author":"Langsted","year":"2019","journal-title":"Pathology."},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15133","article-title":"Non-fasting lipids and cardiovascular disease in those with and without diabetes in Alberta\u2019s Tomorrow Project: A prospective cohort study","volume":"40","author":"Weaver","year":"2023","journal-title":"Diabetes Med"},{"key":"B183","doi-asserted-by":"publisher","first-page":"33","DOI":"10.5339\/gcsp.2015.33","article-title":"The copenhagen city heart study (Osterbroundersogelsen)","volume":"2015","author":"Aguib","year":"2015","journal-title":"Glob Cardiol Sci Pract"},{"key":"B184","first-page":"1","article-title":"Osterbroundersogelsen. A book of ta bles with data from the first examination (1976-78) and a five year follow-up (1981-83). The Copenhagen City Heart Study Group","volume":"41","year":"1989","journal-title":"Scand J Soc Med Suppl."},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.123.319297","article-title":"Independent causal effect of remnant cholesterol on atherosclerotic cardiovascular outcomes: A mendelian randomization study","volume":"43","author":"Navarese","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115770","article-title":"Antibody-based therapeutics for atherosclerosis and cardiovascular diseases","volume":"22","author":"Ji","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212017","article-title":"Vascular extracellular matrix in atherosclerosis","volume":"25","author":"Di Nubila","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1089\/hyb.1995.14.551","article-title":"Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids","volume":"14","author":"Vazquez","year":"1995","journal-title":"Hybridoma."},{"key":"B189","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/glycob\/8.7.695","article-title":"Delineation of the epitope recognized by an antibody specific for N-glycolylneuraminic acid-containing gangliosides","volume":"8","author":"Moreno","year":"1998","journal-title":"Glycobiology."},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1089\/027245701753179785","article-title":"Immunogenetic analysis of variable regions encoding AB1 and gamma-type AB2 antibodies from the NeuGc-containing ganglioside family","volume":"20","author":"Perez","year":"2001","journal-title":"Hybridoma."},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1089\/153685903322328965","article-title":"Chimeric anti-N-glycolyl-ganglioside and its anti-idiotypic MAbs: immunodominance of their variable regions","volume":"22","author":"Lopez-Requena","year":"2003","journal-title":"Hybrid Hybridomics."},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2006.02.020","article-title":"Gangliosides, ab1 and ab2 antibodies I. Towards a molecular dissection of an idiotype-anti-idiotype system","volume":"44","author":"Lopez-Requena","year":"2007","journal-title":"Mol Immunol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2006.03.004","article-title":"Gangliosides, Ab1 and Ab2 antibodies II. Light versus heavy chain: An idiotype-anti-idiotype case study","volume":"44","author":"Lopez-Requena","year":"2007","journal-title":"Mol Immunol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2011.01.008","article-title":"Switching on cytotoxicity by a single mutation at the heavy chain variable region of an anti-ganglioside antibody","volume":"48","author":"Fernandez-Marrero","year":"2011","journal-title":"Mol Immunol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1172\/JCI2265","article-title":"Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding","volume":"101","author":"Boren","year":"1998","journal-title":"J Clin Invest."},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.5.1162","article-title":"Proteoglycans contribution to association of Lp(a) and LDL with smooth muscle cell extracellular matrix","volume":"19","author":"Lundstam","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.25.15753","article-title":"Endothelial cell heparanase modulation of lipoprotein lipase activity. Evidence that heparan sulfate oligosaccharide is an extracellular chaperone","volume":"272","author":"Pillarisetti","year":"1997","journal-title":"J Biol Chem"},{"key":"B198","doi-asserted-by":"publisher","first-page":"e0260954","DOI":"10.1371\/journal.pone.0260954","article-title":"Fc-engineered antibodies with immune effector functions completely abolished","volume":"16","author":"Wilkinson","year":"2021","journal-title":"PloS One"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1089\/hyb.1998.17.527","article-title":"Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody","volume":"17","author":"Vazquez","year":"1998","journal-title":"Hybridoma."},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(02)00041-X","article-title":"A monoclonal antibody against NeuGc-containing gangliosides contains a regulatory idiotope involved in the interaction with B and T cells","volume":"39","author":"Perez","year":"2002","journal-title":"Mol Immunol"},{"key":"B201","article-title":"Towards a network theory of the immune system","author":"Jerne","year":"1974","journal-title":"Ann Immunol (Paris)."},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00232","article-title":"Dose-dependent induction of an idiotypic cascade by anti-glycosaminoglycan monoclonal antibody in apoE(-\/-) mice: association with atheroprotection","volume":"8","author":"Sarduy","year":"2017","journal-title":"Front Immunol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs."},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03151","article-title":"Major histocompatibility complex binding, eluted ligands, and immunogenicity: benchmark testing and predictions","volume":"10","author":"Paul","year":"2019","journal-title":"Front Immunol"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.3390\/antib8040055","article-title":"Antibody structure and function: the basis for engineering therapeutics","volume":"8","author":"Chiu","year":"2019","journal-title":"Antibodies (Basel)."},{"key":"B206","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1208\/s12248-023-00846-x","article-title":"Anti-drug antibody magnitude and clinical relevance using signal to noise (S\/N): bococizumab case study","volume":"25","author":"McCush","year":"2023","journal-title":"AAPS J"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br J Pharmacol"},{"key":"B208","doi-asserted-by":"publisher","first-page":"898769","DOI":"10.1155\/2012\/898769","article-title":"Lipofundin-induced hyperlipidemia promotes oxidative stress and atherosclerotic lesions in New Zealand white rabbits","volume":"2012","author":"Delgado Roche","year":"2012","journal-title":"Int J Vasc Med"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.3109\/10715762.2013.772995","article-title":"The treatment with an anti-glycosaminoglycan antibody reduces aortic oxidative stress in a rabbit model of atherosclerosis","volume":"47","author":"Delgado-Roche","year":"2013","journal-title":"Free Radic Res"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2015.08.027","article-title":"Arresting progressive atherosclerosis by immunization with an anti-glycosaminoglycan monoclonal antibody in apolipoprotein E-deficient mice","volume":"89","author":"Delgado-Roche","year":"2015","journal-title":"Free Radic Biol Med"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00782","article-title":"Atheroregressive potential of the treatment with a chimeric monoclonal antibody against sulfated glycosaminoglycans on pre-existing lesions in apolipoprotein E-deficient mice","volume":"8","author":"Brito","year":"2017","journal-title":"Front Pharmacol"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.147.8.2657","article-title":"Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG","volume":"147","author":"Lund","year":"1991","journal-title":"J Immunol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12111065","article-title":"Familial hypercholesterolemia and lipoprotein(a): A gordian knot in cardiovascular prevention","volume":"12","author":"Koutsogianni","year":"2022","journal-title":"Metabolites"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000067881.26274.BD","article-title":"Prevention of cardiovascular ischemic events: high-risk and secondary prevention","volume":"107","author":"Genest","year":"2003","journal-title":"Circulation."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1485801\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T05:24:00Z","timestamp":1749446640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1485801\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":214,"alternative-id":["10.3389\/fimmu.2025.1485801"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1485801","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"article-number":"1485801"}}